|Table of Contents|

Efficacy analysis of PD-1 monoclonal antibody combined with R-CHOP for first-line treatment of de novo CD5+ diffuse large B-cell lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 06
Page:
988-994
Research Field:
Publishing date:

Info

Title:
Efficacy analysis of PD-1 monoclonal antibody combined with R-CHOP for first-line treatment of de novo CD5+ diffuse large B-cell lymphoma
Author(s):
JIN Shenhe; ZHOU Fengping; ZHANG Jin
Department of Hematology,Sir Run Run Shaw Hospital,College of Medicine,Zhejiang University,Zhejiang Hangzhou 310003,China.
Keywords:
CD5+ diffuse large B-cell lymphoma; PD-1 antibody; R-CHOP
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2025.06.015
Abstract:
Objective:To explore a potential treatment for de novo CD5 positive diffuse large B-cell lymphoma,with the aim of offering more efficacious treatment strategy alternatives for clinical application.Methods:Clinical and pathological data of two patients of CD5 positive diffuse large B-cell lymphoma were collected to analyze clinical characteristics and treatment outcomes.Results:Both two patients achieved early complete remission after receiving 6 cycles treatment with tislelizumab plus R-CHOP regimen.Conclusion:The combination of PD-1 monoclonal antibody and R-CHOP regimen provides a novel first-line treatment protocol for CD5 positive diffuse large B-cell lymphoma.

References:

［1］JAIN P,FAYAD LE,ROSENWALD A,et al.Recent advances in de novo CD5+ diffuse large B cell lymphoma ［J］.Am J Hematol,2013,88(9):798-802.
[2]TIAN Y,SANG W,XU KL.Progress of CD5 positive diffuse large B cell lymphoma ［J］.Journal of Leukemia & Lymphoma,2019,28(6):379-381.
[3]KIM HY,JANG MA,KIM HJ,et al.Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma ［J］.Blood Res,2017,52(3):193-199.
[4]XU Y,SUN W,LI F.De novo CD5+ diffuse large B-cell lymphoma:Biology,mechanism,and treatment advances ［J］.Clin Lymphoma Myeloma Leuk,2020,20(10):e782-e790.
[5]WOZNIALIS N,GIEREJ B,POPAWSKA L,et al.Angiogenesis in CD5-positive diffuse large B cell lymphoma:A morphometric analysis ［J］.Adv Clin Exp Med,2016,25(6):1149-1155.
[6]NA HY,CHOE JY,SHIN SA,et al.Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans:High incidence of BCL2 and MYC double-expressors ［J］.PLoS One,2019,14(10):e0224247.
[7]TANG H,ZHOU H,WEI J,et al.Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma ［J］.Hematology,2019,24(1):446-454.
[8]MIYAZAKI K,YAMAGUCHI M,SUZUKI R,et al.CD5-positive diffuse large B-cell lymphoma:a retrospective study in 337 patients treated by chemotherapy with or without rituximab ［J］.Ann Oncol,2011,22(7):1601-1607.
[9]HU B,NASTOUPIL LJ,LOGHAVI S,et al.De novo CD5+ diffuse large B-cell lymphoma,NOS:clinical characteristics and outcomes in rituximab era ［J］.Leuk Lymphoma,2020,61(2):328-336.
[10]THAKRAL B,MEDEIROS LJ,DESAI P,et al.Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH ［J］.Eur J Haematol,2017,98(4):415-421.
[11]ZHANG F,LI L,ZHANG L,et al.Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens ［J］.Blood Lymphat Cancer,2019,9:33-43.
[12]MIYAZAKI K,ASANO N,YAMADA T,et al.DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma:a single-arm,open-label,phase 2 study ［J］.Haematologica,2019,105(9):231076.
[13]MIYAZAKI K,SAKAI R,IWAKI N,et al.Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL［J］.Cancer Sci,2023,114(6):2689-2691.
[14]TOYAMA K,NAKAYAMA K,TERASAKI S,et al.Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma:a singleinstitute analysis ［J］.J Clin Exp Hematop,2023,63(1):19-24.
[15]ALINARI L,GRU A,QUINION C,et al.De novo CD5+ diffuse large B-cell lymphoma:Adverse outcomes with and without stem cell transplantation in a large,multicenter,rituximab treated cohort ［J］.Am J Hematol,2016,91(4):395-399.
[16]MATSUKI E,YOUNES A.Checkpoint inhibitors and other immune therapies for Hodgkin and non-Hodgkin lymphoma ［J］.Curr Treat Options Oncol,2016,17(6)：31.
[17]肖远喆，张清媛.弥漫性大B细胞淋巴瘤免疫治疗进展［J］.现代肿瘤医学，2022,30（18）：3441-3444. XIAO Yuanzhe，ZHANG Qingyuan.Progress in immunotherapy for diffuse large B-cell lymphoma［J］.Modern Oncology,2022,30（18）：3441-3444.
[18]LEONARD JP,KOLIBABA KS,REEVES JA,et al.Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma ［J］.J Clin Oncol,2017,35(31):3538-3546.
[19]IACOBONI G,ZUCCA E,GHIELMINI M,et al.Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL):a critical review ［J］.Ann Oncol,2018,29(5):1120-1129.
[20]YOUNES A,SEHN LH,JOHNSON P,et al.Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma ［J］.J Clin Oncol,2019,37(15):1285-1295.
[21]JUREZ-SALCEDO LM,SANDOVAL-SUS J,SOKOL L,et al.The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B cell lymphoma:The future is now ［J］.Crit Rev Oncol Hematol,2017,113:52-62.
[22]ANSELL SM,MINNEMA MC,JOHNSON P,et al.Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation:A single-arm,phase II study ［J］.J Clin Oncol,2019,37(6):481-489.
[23]LI X,ZHANG R,LI Q,et al.PD-1 inhibitor combined with chemotherapy as a salvage therapy for refractory DLBCL［J］.Blood,2019,134(Supplement_1):5357.
[24]SETHI T,KOVACH AE,MASON EF,et al.Combination of nivolumab,lenalidomide and rituximab in relapsed/refractory non-germinal center diffuse large B cell lymphoma:Results from a dose-escalation cohort ［J］.Blood,2019,134(Supplement_1):4100.
[25]SMITH SD,TILL BG,SHADMAN MS,et al.Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma:potential for biomarker driven therapy ［J］.Br J Haematol,2020,189(6):1119-1126.
[26]HIRATSUKA T,ITO S,SAKAI R,et al.Proteome analysis of CD5-positive diffuse large B cell lymphoma FFPE tissue reveals downregulation of DDX3X,DNAJB1,and B cell receptor signaling pathway proteins including BTK and immunoglobulins ［J］.Clin Proteomics,2023,20(1):36.
[27]LI L,ZHANG J,CHEN J,et al.B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma ［J］.Blood,2018,132(17):1805-1817.
[28]SHAIN KH,DALTON WS,TAO J.The tumor microenvironment shapes hallmarks of mature B-cell malignancies ［J］.Oncogene,2015,34(36):4673-4682.
[29]SCHERER F,KURTZ DM,NEWMAN AM,et al.Circulating tumor DNA in diffuse large B-cell lymphoma from bench to bedside ［J］.Nature Reviews Clinical Oncology,2019,16(12):733-752.
[30]ALIZADEH AA,ARANDA V,CARTER H,et al.Circulating tumor DNA in lymphoma:Principles and future directions ［J］.Blood,2020,135(5):365-373.
[31]ROSCHEWSKI M,DUNLEAVY K,PITTALUGA S,et al.Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma ［J］.Journal of Clinical Oncology,2015,33(7):771-778.
[32]KURTZ DM,SCHERER F,JIN MC,et al.Circulating tumor DNA clearance during treatment as a predictive and prognostic biomarker for DLBCL patients receiving first-line therapy ［J］.Blood Advances,2021,5(20):5282-5291.
[33]SARKOZY C,HUET S,CARLTON V,et al.Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma:a correlative biomarker study ［J］.The Lancet Oncology,2022,23(9)：1234.
[34]JIANG B,HE J,LYU Y,et al.Genotyping on ctDNA identifies shifts in mutation spectrum between newly diagnosed and relapse refractory DLBCL［J］.Leukemia,2022,36(3):812-820.
[35]RAMAKRISHNAN R,NATH SD,TYAGI A,et al.Circulating tumor DNA in B-cell lymphoma:technical advances,clinical applications,and perspectives for translational research ［J］.Cancer Discovery,2020,10(5):623-634.
[36]ROSSI D,RASI S,SPINA V,et al.Optimizing circulating tumor DNA limits of detection for DLBCL during first line therapy ［J］.Haematologica,2018,103(8):1256-1264.

Memo

Memo:
-
Last Update: 1900-01-01